uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Parallel Changes in Harvey-Bradshaw Index, TNFα, and Intestinal Fatty Acid Binding Protein  in Response to Infliximab in Crohn’s Disease
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology. (Gastroenterology and Hepatology)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology. (Gastroenterology and Hepatology)ORCID iD: 0000-0002-6989-2831
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology. (Gastroenterology and Hepatology)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Gastroenterology/Hepatology. (Gastroenterology and Hepatology)ORCID iD: 0000-0002-5244-0185
Show others and affiliations
2017 (English)In: Gastroenterology Research and Practice, ISSN 1687-6121, E-ISSN 1687-630X, p. 1-8, article id 1745918Article in journal (Refereed) Published
Abstract [en]

Intestinal fatty acid binding protein (I-FABP) indicates barrier integrity. Aims: determine if I-FABP is elevated in active Crohn's disease (CD) and if I-FABP parallels anti-TNF alpha antibody (infliximab) induced lowering of TNF alpha and Harvey-Bradshaw Index (HBI) as potential indicator of mucosal healing. I-FABP distribution along human gut was determined. Serum from 10 CD patients collected during first three consecutive infliximab treatments with matched pretreatment and follow-up samples one week after each treatment and corresponding HBI data were analyzed. I-FABP reference interval was established from 31 healthy subjects with normal gut permeability. I-FABP and TNF alpha were measured by ELISA; CRP was measured by nephelometry. Healthy tissue was used for I-FABP immunohistochemistry. Pretreatment CD patient TNF alpha was 1.6-fold higher than in-house reference interval, while I-FABP was 2.5-fold higher, which lowered at follow-ups. Combining all 30 infusion/follow-up pairs also revealed changes in I-FABP. HBI followed this pattern; CRP declined gradually. I-FABP was expressed in epithelium of stomach, jejunum, ileum, and colon, with the highest expression in jejunum and ileum. I-FABP is elevated in active CD with a magnitude comparable to TNF alpha. Parallel infliximab effects on TNF alpha, HBI, and I-FABP were found. I-FABP may be useful as an intestine selective prognostic marker in CD.

Place, publisher, year, edition, pages
Egypt: Hindawi Publishing Corporation, 2017. p. 1-8, article id 1745918
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:uu:diva-334232DOI: 10.1155/2017/1745918ISI: 000413557400001OAI: oai:DiVA.org:uu-334232DiVA, id: diva2:1159116
Funder
Swedish Research Council, 7916The Karolinska Institutet's Research FoundationThe Swedish Medical Association, SLS-411921; SLS-503131
Note

Title in WoS: Parallel Changes in Harvey-Bradshaw Index, TNF alpha, and Intestinal Fatty Acid Binding Protein in Response to Infliximab in Crohn's Disease

Available from: 2017-11-21 Created: 2017-11-21 Last updated: 2019-04-29Bibliographically approved
In thesis
1. Gastrointestinal Permeability and Motility in Inflammatory Bowel Disease
Open this publication in new window or tab >>Gastrointestinal Permeability and Motility in Inflammatory Bowel Disease
2019 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Synchronized motility, permeability and secretory (hormones and enzymes) events are integral to normal physiology. Smooth muscle syncytium operates with enteric nervous system (ENS) and endocrine signalling to accommodate, mix and control passage of ingested materials. The intestinal epithelial cells (IECs) drive digestion and absorption while repelling harmful compounds.

This thesis investigated GI barrier function (permeability, mucosal integrity), motility and hormonal patterns in inflammatory bowel disease (IBD) by: 1) assessing GI motility using a wireless motility capsule (WMC, SmartPill®) and video capsule endoscopy (VCE, Pillcam®), 2) investigation of intestinal fatty acid binding protein (I-FABP) as a biomarker of Crohn’s disease (CD) disease activity, 3) evaluation of small intestinal permeability in IBD, 4) investigating meal-related WMC motility and simultaneous hormonal (e.g., Ghrelin, GLP-1, GIP, PYY) patterns in IBD. Reference WMC motility values for transit times for gastric emptying, small bowel, orocecal, small+large bowel, colon and whole gut were established. Software-generated estimates and visually determined values were nearly identical. Compared with VCE estimates (represents fasting conditions), the WMC records longer GET and SBTT. Variations in intra-subject reproducibility must be considered in clinical investigations. This data was then used to investigate IBD patients. I-FABP was primarily expressed in the epithelium of the small bowel and to lesser extent also in the colon and stomach. Circulating I-FABP was elevated in active CD with a magnitude comparable to TNFα. I-FABP lowers and rises again in parallel with TNFα and HBI during infliximab treatment. I-FABP can be used as a jejunum and ileum selective prognostic biomarker for monitoring disease activity. Increased small intestine mucosal barrier permeability to lactulose in both CD and UC was found. Sucralose can serve a dual purpose in quantifying small and large intestinal permeability. Small intestinal hyper-permeability was not revealed as a transporter dependent nutrient (riboflavin) malabsorption. Using the WMC, consistent motility disturbances in IBD were limited, as were differences in pH. However, disturbances within many individuals were found. As part of the investigation, defects in gut peptide and metabolic hormone meal responses were found, typically higher plasma levels. No clear associations between hormones and motility were found. Effects on hunger/satiety signaling in IBD are anticipated.

The present thesis shows the utility of the WMC and gut barrier tests in monitoring IBD patients.

Abstract [sv]

Mag-tarmkanalens glatta muskulatur är funktionellt integrerad med enteriska nervsystemet och endokrin signalering för ackommodation, blandning och passage genom mag-tarmkanalen. De intestinala epitelcellerna upprätthåller digestion och absorption, samtidigt med barriärfunktion mot skadliga agens.

Avhandlingen utvärderar patofysiologiska barriärmekanismer vid inflammatorisk tarmsjukdom (IBD) beträffande permeabilitet, förändrad motilitet och hormonella mönster vid Crohns sjukdom (CD) och ulcerös colit (UC) genom att, 1) utvärdera mag-tarmkanalens motilitet med trådlös motilitetskapsel (WMC) och videokapsel endoskopi (VCE), 2) studera I-FABP som biomarkör vid CD avseende distribution i mag-tarmkanalen, samband med sjukdomsktivitet, parallellitet med  TNFα och Harvey-Bradshaw index (HBI) under anti-TNFα-behandling, 3) utvärdera intestinal permeabilitet vid IBD, 4) studera användning av WMC för att registrera motilitet vid måltidssvar och hormonella mönster.

WMC registrerade pH, tryck och temperatur längs hela mag-tarmkanalen. Referensvärden för  ventrikeltömningstid och transittider för tunntarm, colon och totala mag-tarmkanalen etablerades. Dessa värden har använts för utvärdering av IBD. Mjukvaruberäknade värden var lika visuellt avlästa värden. Mätvärden för VCE under fasta visade snabb transit, medan WMC hade längre ventrikeltömningstid och transittid för tunntarm. Intra-individuell variation måste bedömas särskilt vid kliniska undersökningar.

I-FABP lokaliserades till epitelet i tunntarmen, i mindre omfattning i ventrikel och colon. Cirkulerande I-FABP var förhöjt vid aktiv CD, som TNFα. Plasmanivåer av I-FABP följde parallellt TNFα och HBI under behandling och uppföljning. I-FABP kan användas som selektiv prognostisk markör för CD i jejunum och ileum vid monitorering av CD patienter.

Ökad tunntarmspermeabilitet sågs både vid CD och UC med hyperpermeabilitet för laktulos, medan sukralos, som ersättning för laktulos, kunde mäta permeabilitet i både tunntarm och colon. Hyperpermeabiliteten medför ingen generell malabsorption eftersom absorptionen av riboflavin var normal, och beror av specifika transportmekanismer i tunntarmen.

Med hjälp av WMC kunde endast begränsade avvikelser i motiliteten vid IBD registreras, även för pH. Hos enskilda individer kunde tydliga avvikelser ses. Dessutom noterades generellt förhöjda gastrointestinala och metabola peptidhormoner samtidigt med ett bevarat måltidssvar. Samband mellan hormonnivåer och motilitetsavvikelser saknades, men sannolikt har hormonnivåerna betydelse för hunger och mättnad.

Den sammantagna bilden visar användbarheten av WMC och permeabilitetstest för att bedöma patofysiologiska funktioner i mag-tarmkanalen. I-FABP kan spåra sjukdomsaktivitet i tunntarmen, medan permeabilitetstest ger information selektivt om sjukdom i tunntarm och colon. Användning av WMC tillsammans med mönster av hormonfrisättning kan ge information om motilitetsstörningar och sannolikt förändrad aptitreglering.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2019. p. 62
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 1577
Keywords
Gastrointestinal motility, intestinal permeability, Mucosal, Ghrelin
National Category
Medical and Health Sciences
Research subject
Medical Science
Identifiers
urn:nbn:se:uu:diva-382486 (URN)978-91-513-0671-1 (ISBN)
Public defence
2019-06-14, Enghoffsalen, Ing 50 bv, Akademiska sjukhuset, Uppsala, 09:00 (English)
Opponent
Supervisors
Available from: 2019-05-23 Created: 2019-04-25 Last updated: 2019-06-17

Open Access in DiVA

fulltext(24877 kB)72 downloads
File information
File name FULLTEXT01.pdfFile size 24877 kBChecksum SHA-512
66bec4474a14df2a6c940cb2473d17eaeaf30a780faecf04feb1ab03090ad806ac7bc176db3660262035129065d9949aa17cebbca4ec95a8cd1c9d0867fea432
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Al-Saffar, AnasGannavarapu, Venkata RamDiaz Tartera, Hetzel O.Hellström, Per M.Webb, Dominic-Luc

Search in DiVA

By author/editor
Al-Saffar, AnasMeijer, Carl HampusGannavarapu, Venkata RamHall, GustavLi, YichenDiaz Tartera, Hetzel O.Ljung, TryggveHellström, Per M.Webb, Dominic-Luc
By organisation
Gastroenterology/Hepatology
In the same journal
Gastroenterology Research and Practice
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar
Total: 72 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 449 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf